BioAge Labs — Third Quarter 2026 Earnings Summary

BioAge Labs reported a net loss of $33.5 million for the third quarter of 2026, driven primarily by an $11.7 million increase in research and development expenses associated with its BGE-102 clinical trials. The company advanced its lead candidate BGE-102 by dosing the first participant in the Phase 2 QUELL-DME trial for diabetic macular edema and completing enrollment in the Phase 2 QUELL-CV trial for obesity. Collaboration revenue decreased to $0.3 million due to a cumulative catch-up adjustment related to an amendment with Novartis. As of September 30, 2026, BioAge held approximately $352.3 million in cash and marketable securities, which is projected to fund operations through 2029.